Publication
Title
The effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease
Author
Institution/Organisation
Multi-Centre Renal Bone Disease
Abstract
Lanthanum carbonate (Fosrenol(TM), Shire Pharmaceuticals) is a novel treatment for hyperphosphataemia. In this open-label study, we compared the effects of lanthanum carbonate and calcium carbonate on bone in dialysis patients. Paired bone biopsies were taken, at baseline and after 1 year of treatment, in 33 lanthanum- and 30 calcium-treated patients. Serum phosphate levels were well controlled in both groups and lanthanum carbonate was well tolerated. After 1 year of lanthanum carbonate treatment, five of seven patients with low bone turnover at baseline and four of five with hyperparathyroidism developed a more normal bone turnover. Only one; lanthanum patient developed adynamic bone compared with six in the calcium group. Analyses of data so far indicate that lanthanum carbonate does not have any adverse effects on bone.
Language
English
Source (book)
Proceedings 9th Asian Pacific Congress of Nephrology (16-20 February 2003)
Publication
Bologna : Monduzzi, 2003
ISBN
88-323-3101-2
Volume/pages
p. 191-194
ISI
000182539200037
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 08.10.2008
Last edited 22.07.2017
To cite this reference